
Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.
Andre Goy, MD, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide plus rituximab, also known as the R<sup>2</sup> regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.<br />
Andre Goy, MD, chief, division of lymphoma, chairman and director, John Theurer Cancer Center, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide (Revlimid) plus rituximab (Rituxan), also known as the R2regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.
In this patient population, rituximab monotherapy was standard treatment, but this was not an appealing option for older patients. The data support R2






